Chinese Regulator Approves Essex Bio-Technology's Unit's Eye Drops for Registration, Commercialization in China

MT Newswires Live12-24 21:19

China's National Medical Products Administration approved Essex Bio-Technology's (HKG:1061) subsidiary Guangdong Hanfeng Baisheng Pharmaceutical's sodium hyaluronate eye drops for registration and commercialization in mainland China, according to a Tuesday filing with the Hong Kong Stock Exchange.

The approval excludes the Hong Kong Special Administrative Region, the Macao Special Administrative Region, and Taiwan.

The preservative-free drug is used for eye conditions such as Sjögren's syndrome which causes dry eyes, Stevens-Johnson syndrome which affects mucous membranes, and other injuries caused by surgery, drugs, or contact lens use, the filing said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493086715?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-24 21:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493086715","market":"fut","top_or_hot":-1,"title":"Chinese Regulator Approves Essex Bio-Technology's Unit's Eye Drops for Registration, Commercialization in China","media":"MT Newswires Live","content":"<html><body><p> China's National Medical Products Administration approved Essex Bio-Technology's (HKG:1061) subsidiary Guangdong Hanfeng Baisheng Pharmaceutical's sodium hyaluronate eye drops for registration and commercialization in mainland China, according to a Tuesday filing with the Hong Kong Stock Exchange.</p><p>The approval excludes the Hong Kong Special Administrative Region, the Macao Special Administrative Region, and Taiwan.</p><p>The preservative-free drug is used for eye conditions such as Sjögren's syndrome which causes dry eyes, Stevens-Johnson syndrome which affects mucous membranes, and other injuries caused by surgery, drugs, or contact lens use, the filing said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Regulator Approves Essex Bio-Technology's Unit's Eye Drops for Registration, Commercialization in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Regulator Approves Essex Bio-Technology's Unit's Eye Drops for Registration, Commercialization in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-24 21:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>China's National Medical Products Administration approved Essex Bio-Technology's (HKG:1061) subsidiary Guangdong Hanfeng Baisheng Pharmaceutical's sodium hyaluronate eye drops for registration and ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2493086715","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493086715","pubTimestamp":1735046386,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China's National Medical Products Administration approved Essex Bio-Technology's  subsidiary Guangdong Hanfeng Baisheng Pharmaceutical's sodium hyaluronate eye drops for registration and commercialization in mainland China, according to a Tuesday filing with the Hong Kong Stock Exchange.The approval excludes the Hong Kong Special Administrative Region, the Macao Special Administrative Region, and Taiwan.The preservative-free drug is used for eye conditions such as Sjgren's syndrome which causes dry eyes, Stevens-Johnson syndrome which affects mucous membranes, and other injuries caused by surgery, drugs, or contact lens use, the filing said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","01061":"亿胜生物科技"},"translate_title":"中国监管机构批准Essex Bio-Technology子公司滴眼液在中国注册和商业化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01061":0.9},"content_text":"China's National Medical Products Administration approved Essex Bio-Technology's (HKG:1061) subsidiary Guangdong Hanfeng Baisheng Pharmaceutical's sodium hyaluronate eye drops for registration and commercialization in mainland China, according to a Tuesday filing with the Hong Kong Stock Exchange.The approval excludes the Hong Kong Special Administrative Region, the Macao Special Administrative Region, and Taiwan.The preservative-free drug is used for eye conditions such as Sjögren's syndrome which causes dry eyes, Stevens-Johnson syndrome which affects mucous membranes, and other injuries caused by surgery, drugs, or contact lens use, the filing said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493086715"}